CN115094523A - 用于治疗性抗体表征的基于阵列的肽文库 - Google Patents

用于治疗性抗体表征的基于阵列的肽文库 Download PDF

Info

Publication number
CN115094523A
CN115094523A CN202210757923.6A CN202210757923A CN115094523A CN 115094523 A CN115094523 A CN 115094523A CN 202210757923 A CN202210757923 A CN 202210757923A CN 115094523 A CN115094523 A CN 115094523A
Authority
CN
China
Prior art keywords
peptide
peptides
antibody
competing
patterned mask
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210757923.6A
Other languages
English (en)
Chinese (zh)
Inventor
马修·格雷宁
大卫·史密斯
高拉夫·萨伊尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cooper Science
Original Assignee
Cooper Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cooper Science filed Critical Cooper Science
Publication of CN115094523A publication Critical patent/CN115094523A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/14—Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/14—Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support
    • C40B50/18—Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support using a particular method of attachment to the solid support
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00623—Immobilisation or binding
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00675—In-situ synthesis on the substrate
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00709—Type of synthesis
    • B01J2219/00711—Light-directed synthesis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00725—Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Structural Engineering (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
CN202210757923.6A 2016-04-01 2017-03-31 用于治疗性抗体表征的基于阵列的肽文库 Pending CN115094523A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662317353P 2016-04-01 2016-04-01
US62/317,353 2016-04-01
US201762472504P 2017-03-16 2017-03-16
US62/472,504 2017-03-16
CN201780034482.4A CN109313184A (zh) 2016-04-01 2017-03-31 用于治疗性抗体表征的基于阵列的肽文库
PCT/US2017/025546 WO2017173365A1 (en) 2016-04-01 2017-03-31 Array-based peptide libraries for therapeutic antibody characterization

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780034482.4A Division CN109313184A (zh) 2016-04-01 2017-03-31 用于治疗性抗体表征的基于阵列的肽文库

Publications (1)

Publication Number Publication Date
CN115094523A true CN115094523A (zh) 2022-09-23

Family

ID=59966524

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210757923.6A Pending CN115094523A (zh) 2016-04-01 2017-03-31 用于治疗性抗体表征的基于阵列的肽文库
CN201780034482.4A Pending CN109313184A (zh) 2016-04-01 2017-03-31 用于治疗性抗体表征的基于阵列的肽文库

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780034482.4A Pending CN109313184A (zh) 2016-04-01 2017-03-31 用于治疗性抗体表征的基于阵列的肽文库

Country Status (9)

Country Link
US (3) US20190113522A1 (https=)
EP (1) EP3436825A4 (https=)
JP (1) JP2019520421A (https=)
KR (1) KR20180136464A (https=)
CN (2) CN115094523A (https=)
AU (1) AU2017240164A1 (https=)
CA (1) CA3019596A1 (https=)
SG (1) SG11201808628PA (https=)
WO (1) WO2017173365A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2430574A1 (en) 2009-04-30 2012-03-21 Patientslikeme, Inc. Systems and methods for encouragement of data submission in online communities
AU2017359450A1 (en) 2016-11-09 2019-05-30 HealthTell, Inc. Coatings with tunable amine density
WO2018089554A1 (en) 2016-11-09 2018-05-17 Healthtell Inc. Pre-assembled, protected, chemically stable, chemoselective linkers
WO2019055879A2 (en) 2017-09-15 2019-03-21 PatientsLikeMe Inc. SYSTEMS AND METHODS FOR COLLECTING AND ANALYZING COMPLETE MEDICAL INFORMATION
TW201923091A (zh) * 2017-10-09 2019-06-16 美商健康堤爾股份有限公司 用於定向免疫反應的免疫原及由此產生之抗體
WO2019074940A1 (en) * 2017-10-09 2019-04-18 Healthtell Inc. INTEGRATED PLATFORM FOR SELECTING LIAISON PARTNERS BASED ON TARGET AND SPECIFICITY INFORMATION
WO2019157362A1 (en) * 2018-02-09 2019-08-15 Healthtell Inc. Array-based cyclic peptide libraries
US11894139B1 (en) 2018-12-03 2024-02-06 Patientslikeme Llc Disease spectrum classification
CN115116543B (zh) * 2022-04-18 2025-08-05 腾讯科技（深圳）有限公司 抗原抗体结合位点确定方法、装置、设备和存储介质

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060210452A1 (en) * 1989-06-07 2006-09-21 Affymax Technologies, N.V., A Netherlands Antilles Corporation Very large scale immobilized polymer synthesis
US7270950B2 (en) * 1997-01-21 2007-09-18 The General Hospital Corporation Nucleic acid-protein fusions and methods of making and selecting fusions
WO2014062981A1 (en) * 2012-10-17 2014-04-24 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University In situ chemical patterning
CN104379821A (zh) * 2012-03-31 2015-02-25 艾比玛特生物医药（上海）有限公司 肽和抗体文库及其应用
US20160060687A1 (en) * 2014-07-18 2016-03-03 Cdi Laboratories, Inc. Methods and compositions to identify, quantify, and characterize target analytes and binding moieties
US20160090592A1 (en) * 2013-08-05 2016-03-31 Twist Bioscience Corporation De novo synthesized gene libraries

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424186A (en) * 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
KR100529600B1 (ko) * 2003-01-23 2005-11-22 정만길 디옥소아테미시닌 유사체, 그의 제조방법 및 그를포함하는 항암제
US8217154B2 (en) * 2005-02-23 2012-07-10 Lipoxen Technologies Limited Activated sialic acid derivatives for protein derivatisation and conjugation
RU2684595C2 (ru) * 2012-07-04 2019-04-09 Ф.Хоффманн-Ля Рош Аг Ковалентно связанные конъюгаты антиген-антитело

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060210452A1 (en) * 1989-06-07 2006-09-21 Affymax Technologies, N.V., A Netherlands Antilles Corporation Very large scale immobilized polymer synthesis
US7270950B2 (en) * 1997-01-21 2007-09-18 The General Hospital Corporation Nucleic acid-protein fusions and methods of making and selecting fusions
CN104379821A (zh) * 2012-03-31 2015-02-25 艾比玛特生物医药（上海）有限公司 肽和抗体文库及其应用
WO2014062981A1 (en) * 2012-10-17 2014-04-24 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University In situ chemical patterning
US20160090592A1 (en) * 2013-08-05 2016-03-31 Twist Bioscience Corporation De novo synthesized gene libraries
US20160060687A1 (en) * 2014-07-18 2016-03-03 Cdi Laboratories, Inc. Methods and compositions to identify, quantify, and characterize target analytes and binding moieties

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
夏晴, 仲人前, 侯晓菁, 薛菖, 陈军, 孔宪涛: "一种新的胰腺癌相关性自身抗原PAA47的纯化和鉴定", 上海免疫学杂志, no. 01, 20 January 2003 (2003-01-20), pages 32 - 35 *

Also Published As

Publication number Publication date
SG11201808628PA (en) 2018-10-30
JP2019520421A (ja) 2019-07-18
AU2017240164A1 (en) 2018-11-15
WO2017173365A1 (en) 2017-10-05
US20240159770A1 (en) 2024-05-16
EP3436825A1 (en) 2019-02-06
CN109313184A (zh) 2019-02-05
CA3019596A1 (en) 2017-10-05
US20190113522A1 (en) 2019-04-18
US20240077492A1 (en) 2024-03-07
EP3436825A4 (en) 2020-03-18
KR20180136464A (ko) 2018-12-24

Similar Documents

Publication Publication Date Title
US20240159770A1 (en) Computer-based methods of designing patterned mask
Sun et al. Recent advances in microarray technologies for proteomics
US20180259510A1 (en) Non-covalent patterned chemical features and use thereof in maldi-based quality control
Sun et al. Research advances in hydrogen–deuterium exchange mass spectrometry for protein epitope mapping
Moreau et al. PEPOP: computational design of immunogenic peptides
Vallejo et al. A modified drift tube ion mobility-mass spectrometer for charge-multiplexed collision-induced unfolding
CN114585918A (zh) 中尺度工程化肽和选择方法
Peri et al. Rational epitope design for protein targeting
JP2017504795A (ja) タンパク質に対するペプチドバインダーの系統的探索、成熟化、および伸長
AU2017357818A1 (en) Methods for identifying candidate biomarkers
Deslignière et al. High-resolution IMS–MS to assign additional disulfide bridge pairing in complementarity-determining regions of an IgG4 monoclonal antibody
EP3642233A2 (en) Immunosignatures for differential diagnosis
CA3028960A1 (en) Methods for differential diagnosis of autoimmune diseases
JP2016222725A (ja) モノクローナル抗体を生成し、検証し、そして使用するための方法およびシステム
Zhu et al. Molecular recognition mechanism of an anti-amatoxins mAb and its application in centrifugal disk-based immunoassay
Li et al. A rare monoclonal antibody discovery based on indirect competitive screening of a single hapten-specific rabbit antibody secreting cell
Wang et al. Application of N-terminal site-specific biotin and digoxigenin conjugates to clinical anti-drug antibody assay development
TW201922771A (zh) 用於源自目標及特異性訊息之結合配偶體選擇的整合平台
WO2025102085A1 (en) Methods and systems for detecting one or more analytes associated with one or more autoimmune diseases
HK40004261A (en) Array-based peptide libraries for therapeutic antibody characterization
CN119384696A (zh) 分离反配体的方法
Garcia et al. Current trends in biotherapeutic higher order structure characterization by irreversible covalent footprinting mass spectrometry
WO2019074934A1 (en) IMMUNOGENS FOR DIRECTED IMMUNE RESPONSE AND ANTIBODIES THEREFROM
Trier Characterization of peptide antibodies by epitope mapping using resin-bound and soluble peptides
CN117894366B (zh) 基于计算模拟筛选抗体的方法及所得抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination